1. EachPod

ReachMD CME - Podcast

ReachMD CME

 ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Health Science & Medicine Medicine
Update frequency
every day
Episodes
499
Years Active
2019 - 2025
Share to:
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents

Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents

Fri 30 Aug 2024
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers

Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers

CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/

This online…

Fri 30 Aug 2024
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

Fri 30 Aug 2024
Diversity in HER2 Expression Among Gynecologic Cancers

Diversity in HER2 Expression Among Gynecologic Cancers

CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/

This online MinuteCE program…

Fri 30 Aug 2024
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability

Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability

CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/frontline-fixed-duration-therapy-in-cll-improving-outcomes-and-tolerability/26495/

Determi…

Fri 16 Aug 2024
Mutational Testing to Guide Therapy in CLL: Why and When

Mutational Testing to Guide Therapy in CLL: Why and When

CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/mutational-testing-to-guide-therapy-in-cll-why-and-when/26496/

Determining the optimal tre…

Fri 16 Aug 2024
Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations

Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations

Fri 16 Aug 2024
Risk-Stratification in Newly Diagnosed CLL

Risk-Stratification in Newly Diagnosed CLL

CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-in-newly-diagnosed-cll/26494/

Determining the optimal treatment regime…

Fri 16 Aug 2024
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting

Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting

CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/fixed-duration-therapy-in-the-relapsedrefractory-cll-setting/26501/

Determining the optima…

Fri 16 Aug 2024
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies

The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies

Fri 16 Aug 2024
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk

Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk

Fri 16 Aug 2024
Combination Therapy for CLL: What Evidence Do We Have?

Combination Therapy for CLL: What Evidence Do We Have?

CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/

Determining the optimal treatm…

Fri 16 Aug 2024
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach

Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach

Fri 16 Aug 2024
MRD Testing to Guide Treatment Considerations in CLL

MRD Testing to Guide Treatment Considerations in CLL

CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/mrd-testing-to-guide-treatment-considerations-in-cll/26499/

Determining the optimal treatm…

Fri 16 Aug 2024
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

Tue 13 Aug 2024
Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis

Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis

Fri 09 Aug 2024
Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey

Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey

Fri 09 Aug 2024
The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences

The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences

Fri 09 Aug 2024
Creating a Practice Environment That Enhances Healthcare Equality for All Patients

Creating a Practice Environment That Enhances Healthcare Equality for All Patients

Fri 09 Aug 2024
Case in Point: The Use of GnRH Antagonists Pre- and/or Post-Surgery and the Potential Consequences of Repeat Surgery

Case in Point: The Use of GnRH Antagonists Pre- and/or Post-Surgery and the Potential Consequences of Repeat Surgery

Fri 09 Aug 2024
Disclaimer: The podcast and artwork embedded on this page are the property of ReachMD. This content is not affiliated with or endorsed by eachpod.com.